On Monday, Aquestive Therapeutics Inc (NASDAQ: AQST) was -5.50% drop from the session before settling in for the closing price of $5.09. A 52-week range for AQST has been $1.84 – $6.23.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -4.81% over the past five years. When this article was written, the company’s average yearly earnings per share was at -234.62%. With a float of $77.56 million, this company’s outstanding shares have now reached $91.18 million.
Let’s look at the performance matrix of the company that is accounted for 135 employees. In terms of profitability, gross margin is 69.39%, operating margin of -35.83%, and the pretax margin is -59.58%.
Aquestive Therapeutics Inc (AQST) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Aquestive Therapeutics Inc stocks. The insider ownership of Aquestive Therapeutics Inc is 14.94%, while institutional ownership is 45.31%. The most recent insider transaction that took place on Nov 26 ’24, was worth 214. In this transaction Chief Operating Officer of this company sold 44 shares at a rate of $4.87, taking the stock ownership to the 0 shares. Before that another transaction happened on Mar 15 ’24, when Company’s Chief Innovation/Tech Officer sold 50,000 for $6.00, making the entire transaction worth $300,000. This insider now owns 984,476 shares in total.
Aquestive Therapeutics Inc (AQST) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -234.62% per share during the next fiscal year.
Aquestive Therapeutics Inc (NASDAQ: AQST) Trading Performance Indicators
You can see what Aquestive Therapeutics Inc (AQST) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.91. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.34.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.45, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.56 in one year’s time.
Technical Analysis of Aquestive Therapeutics Inc (AQST)
Aquestive Therapeutics Inc (NASDAQ: AQST) saw its 5-day average volume 1.54 million, a negative change from its year-to-date volume of 1.74 million. As of the previous 9 days, the stock’s Stochastic %D was 76.36%. Additionally, its Average True Range was 0.33.
During the past 100 days, Aquestive Therapeutics Inc’s (AQST) raw stochastic average was set at 68.67%, which indicates a significant increase from 48.65% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 61.09% in the past 14 days, which was lower than the 71.57% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.98, while its 200-day Moving Average is $4.01. Nevertheless, the first resistance level for the watch stands at $5.14 in the near term. At $5.47, the stock is likely to face the second major resistance level. The third major resistance level sits at $5.65. If the price goes on to break the first support level at $4.63, it is likely to go to the next support level at $4.44. The third support level lies at $4.11 if the price breaches the second support level.
Aquestive Therapeutics Inc (NASDAQ: AQST) Key Stats
There are 91,178K outstanding shares of the company, which has a market capitalization of 432.62 million. As of now, sales total 50,580 K while income totals -7,870 K. Its latest quarter income was 13,540 K while its last quarter net income were -11,510 K.
